BLLN (BillionToOne) OCF Margin %: 14.24% (As of Mar. 2026)


BLLN BillionToOne Inc BLLN
13 GF Score
Price $122.33
! 5 Warning Signs
View Full Analysis

What is BillionToOne OCF Margin %?

BillionToOne BLLN +2.04% 13 OCF Margin % is 14.24% as of Mar. 2026. GuruFocus rates BLLN with a GF Score™ of 13/100. The stock has 5 warning signs investors should review. Among 203 Medical Diagnostics & Research companies, BillionToOne ranks better than 59.11% on this metric.

OCF Margin % is calculated as Cash Flow from Operations divided by its Revenue. BillionToOne's Cash Flow from Operations for the three months ended in Mar. 2026 was $15.4 Mil. BillionToOne's Revenue for the three months ended in Mar. 2026 was $108.4 Mil. Therefore, BillionToOne's OCF Margin % for the quarter that ended in Mar. 2026 was 14.24%.

As of today, BillionToOne's current OCF Yield % is 0.66%.

The historical rank and industry rank for BillionToOne's OCF Margin % or its related term are showing as below:

BLLN' s OCF Margin % Range Over the Past 10 Years
Min: -74.83   Med: -27.12   Max: 8.06
Current: 10.55

During the past 3 years, the highest OCF Margin % of BillionToOne was 8.06%. The lowest was -74.83%. And the median was -27.12%.

BLLN's OCF Margin % is ranked better than
59.11% of 203 companies
in the Medical Diagnostics & Research industry
Industry Median: 4.67 vs BLLN: 10.55

BillionToOne OCF Margin % Related Terms

BillionToOne OCF Margin % Historical Data

* Premium members only.

The historical data trend for BillionToOne's OCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BillionToOne OCF Margin % Chart

BillionToOne Annual Data
Trend Dec23 Dec24 Dec25
OCF Margin %
-74.83 -27.12 8.06

BillionToOne Quarterly Data
Dec23 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
OCF Margin % Get a 7-Day Free Trial 4.45 1.78 11.97 11.24 14.24

BLLN vs SHC, VCYT, RDNT: OCF Margin % Comparison

For the Diagnostics & Research subindustry, BillionToOne's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BillionToOne OCF Margin % vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, BillionToOne's OCF Margin % distribution charts can be found below:

* The bar in red indicates where BillionToOne's OCF Margin % falls into.


BLLN
13GF Score
BillionToOne Inc BLLN
OCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BillionToOne OCF Margin % Calculation

OCF Margin % is the ratio of Cash Flow from Operations divided by net sales or Revenue, usually presented in percent.

BillionToOne's OCF Margin for the fiscal year that ended in Dec. 2025 is calculated as

OCF Margin=Cash Flow from Operations (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=24.595/305.112
=8.06 %

BillionToOne's OCF Margin for the quarter that ended in Mar. 2026 is calculated as

OCF Margin=Cash Flow from Operations (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=15.43/108.388
=14.24 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about OCF Margin % →
What does a OCF Margin % of 14.24% mean?
BillionToOne (BLLN) has a OCF Margin % of 14.24% as of Mar. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on BillionToOne and its competitors. According to the industry distribution chart, BillionToOne ranks #83 out of 203 companies in the Medical Diagnostics & Research industry, placing it in the top 40.9%.
Is BillionToOne's OCF Margin % too high?
BillionToOne's current OCF Margin % is 14.24%. The Medical Diagnostics & Research industry median OCF Margin % is 4.67. BillionToOne's value of 14.24% is 204.9% above this industry median. Based on the distribution chart, BillionToOne ranks #83 out of 203 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, BillionToOne has a GF Score™ of 13/100, reflecting its overall financial health beyond just this single metric.
How does BillionToOne's OCF Margin % compare to SHC and VCYT?
According to the Medical Diagnostics & Research industry distribution chart, BillionToOne ranks #83 out of 203 companies for OCF Margin %. This puts BillionToOne in the upper half of its industry. The industry median OCF Margin % is 4.67. BillionToOne's value of 14.24% is 204.9% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Medical Diagnostics & Research company?
The median OCF Margin % among Medical Diagnostics & Research companies is 4.67, based on 203 companies in the industry. Companies in the top quartile (top 25%) have a OCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BillionToOne's current OCF Margin % of 14.24% is 204.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on BillionToOne and its competitors. For the Medical Diagnostics & Research industry, the median OCF Margin % is 4.67 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BillionToOne's current OCF Margin % is 14.24%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BillionToOne stock overvalued right now?
BillionToOne (BLLN) has a current OCF Margin % of 14.24%. The current OCF Margin % is 14.24% and 204.9% above the Medical Diagnostics & Research industry median of 4.67. BillionToOne's overall GF Score™ is 13/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For BillionToOne (BLLN), the current OCF Margin % is 14.24% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

BillionToOne Business Description

Address 1035 O’Brien Drive, Menlo Park, CA, USA, 94025
BillionToOne Inc is a molecular diagnostics company. It offers a portfolio of ultrasensitive tests covering prenatal genetic testing, cancer therapy selection, and response monitoring, which are based on its Quantitative Counting Templates (QCT) molecular counting platform. The company's product portfolio comprises UNITY, a portfolio of prenatal testing products that can conduct fetal risk analysis without requiring a paternal sample; Northstar Select, a ultrasensitive liquid biopsy test that provides insights into appropriate therapies for stage III or IV cancer patients; and Northstar Response, a tissue-free, pan-cancer, liquid biopsy test that measures several genomic loci uniquely methylated in cancer to provide insight into dynamic changes in therapy response.
13GF Score

Get the complete analysis for BLLN

OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$122.33
Price